Osimertinib – effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors

Non-small cell lung cancer (NSCLC) driven by activating mutations in epidermal growth factor receptor (EGFR) constitutes up to 10% of NSCLC cases. According to the NCCN recommendations, all patients (with the exception of smoking patients with squamous cell lung cancer) should be screened for the pr...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:	Contemporary Oncology
المؤلفون الرئيسيون:	Marcin Skrzypski, Amelia Szymanowska-Narloch, Rafał Dziadziuszko
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Termedia Publishing House 2017-09-01
الموضوعات:	lung cancer chemotherapy TKI inhibitors osimertinib
الوصول للمادة أونلاين:	https://www.termedia.pl/Osimertinib-effective-treatment-of-NSCLC-with-activating-EGFR-mutations-after-progression-on-EGFR-tyrosine-kinase-inhibitors,3,30597,1,1.html

مواد مشابهة

Comparison of first-generation EGFR-TKIs combined with low-dose bevacizumab versus osimertinib in untreated advanced EGFR-mutated NSCLC
حسب: Yingqi Xu, وآخرون
منشور في: (2025-12-01)

Real-world Treatment Patterns in Patients with EGFR Mutation-positive NSCLC Receiving a First-Line, First- or Second-generation EGFR Tyrosine Kinase Inhibitor in South Korea and Taiwan
حسب: Jae Cheol Lee, وآخرون
منشور في: (2021-05-01)

Induction EGFR tyrosine kinase inhibitors prior to definitive chemoradiotherapy in unresectable stage III EGFR-mutated non-small cell lung cancer
حسب: Jacqueline V. Aredo, وآخرون
منشور في: (2022-01-01)

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
حسب: Igor Makhlin, وآخرون
منشور في: (2019-11-01)

Prolonged Response to Osimertinib in EGFR-Mutated Metastatic Urothelial Carcinoma, a Case Report
حسب: Sareen T. Ali, وآخرون
منشور في: (2024-07-01)

EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis
حسب: Ao Liu, وآخرون
منشور في: (2024-11-01)

Osimertinib plus chemotherapy versus osimertinib for patients with advanced NSCLC with concomitant EGFR and TP53 mutations: a prospective cohort study
حسب: Jixian Li, وآخرون
منشور في: (2025-07-01)

Real-world outcomes of treatment strategy between first-line osimertinib, first/second-generation EGFR-TKIs followed by osimertinib and without osimertinib in advanced EGFR-mutant NSCLC
حسب: Y. Uehara, وآخرون
منشور في: (2024-09-01)

Different incidence of interstitial lung disease according to different kinds of EGFR‐tyrosine kinase inhibitors administered immediately before and/or after anti‐PD‐1 antibodies in lung cancer
حسب: Takahiro Uchida, وآخرون
منشور في: (2019-04-01)

Distinct Progression and Efficacy of First-Line Osimertinib Treatment According to Mutation Subtypes in Metastatic NSCLC Harboring EGFR Mutations
حسب: Yuki Takeyasu, MD, وآخرون
منشور في: (2024-02-01)

NCOA-RET fusion as a secondary resistance mechanism to osimertinib in complex EGFR-mutated lung adenocarcinoma: Case report and review of literature
حسب: Alberto P. Romagnolo, وآخرون
منشور في: (2023-06-01)

Association of PD‐L1 tumor proportion score ≥20% with early resistance to osimertinib in patients with EGFR‐mutated NSCLC
حسب: Yusuke Hamakawa, وآخرون
منشور في: (2023-09-01)

First‐Line Osimertinib for EGFR‐Mutated Squamous Cell Lung Carcinoma: A Case Report
حسب: Yugo Matsumura, وآخرون
منشور في: (2025-07-01)

Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR‐mutant NSCLC patient with acquired LMNA‐NTRK1 fusion following osimertinib resistance
حسب: Jiao‐Li Wang, وآخرون
منشور في: (2022-11-01)

Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs
حسب: Hsu-Yuan Chen, وآخرون
منشور في: (2024-10-01)

Multimodal prediction of tyrosine kinase inhibitors therapy outcomes in advanced EGFR-mutated NSCLC patients
حسب: Xiaodong Chai, وآخرون
منشور في: (2025-08-01)

Aspirin sensitizes osimertinib‐resistant NSCLC cells in vitro and in vivo via Bim‐dependent apoptosis induction
حسب: Rui Han, وآخرون
منشور في: (2020-06-01)

Real-World Experience of First-Line Osimertinib in EGFR Mutated Non-Small Cell Lung Cancers from a Tertiary Cancer Center, India
حسب: Atul Tiwari, وآخرون

Osimertinib-Induced Hepatitis Following Immunotherapy in a Patient with Lung Adenocarcinoma Harboring De Novo EGFR Exon 19 Deletion and T790M Mutations: A Case Report
حسب: Bradley Steiner, وآخرون
منشور في: (2025-06-01)

Life-Threatening Myositis in a Patient With EGFR-Mutated NSCLC on Osimertinib: Case Report
حسب: Fionnuala Crowley, MB BCh BAO, وآخرون
منشور في: (2022-01-01)

Successful osimertinib rechallenge without concomitant corticosteroids after osimertinib-induced pneumonitis
حسب: Taisuke Ito, وآخرون
منشور في: (2024-01-01)

SOS2 modulates the threshold of EGFR signaling to regulate osimertinib efficacy and resistance in lung adenocarcinoma
حسب: Patricia L. Theard, وآخرون
منشور في: (2024-03-01)

Adenocarcinoma Harboring EGFR-RAD51 Fusion Treated With Osimertinib: A Case Report
حسب: Sunny Y. Lai, MD, وآخرون
منشور في: (2024-04-01)

Clinical Management in NSCLC Patients With EGFR Mutation After Osimertinib Progression With Unknown Resistance Mechanisms
حسب: Xin Liao, وآخرون
منشور في: (2024-10-01)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
حسب: Qingli Cui, وآخرون
منشور في: (2022-01-01)

Osimertinib‐induced BRAF mutation in a single metastatic lesion among multiple pulmonary lesions in a case of lung cancer with EGFR exon 19 deletion
حسب: Hiroyuki Miura, وآخرون
منشور في: (2024-08-01)

Osimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced EGFR-Mutated NSCLC
حسب: Judith L. Gulikers, MSc, وآخرون
منشور في: (2024-04-01)

Primary Resistance to EGFR Tyrosine Kinase Inhibitors (TKIs): Contexts and Comparisons in EGFR-Mutated Lung Cancer
حسب: Keigo Kobayashi
منشور في: (2023-12-01)

Addition of bevacizumab to EGFR tyrosine kinase inhibitors in advanced NSCLC: an updated systematic review and meta-analysis
حسب: Haosheng Zheng, وآخرون
منشور في: (2024-01-01)

The Prediction Of Epidermal Growth Factor Receptor Mutation And Prognosis Of EGFR Tyrosine Kinase Inhibitor By Serum Ferritin In Advanced NSCLC
حسب: Wu Z, وآخرون
منشور في: (2019-10-01)

Design, synthesis, and biological evaluation of Osimertinib–Cy7 (OSA-Cy7) conjugate as potential theranostic agent targeting activating EGFR mutations
حسب: Ying Dong, وآخرون
منشور في: (2025-08-01)

BRAF Fusion as Resistance Mechanism to Osimertinib in EGFR-Mutated NSCLC: A Case Report and Review of Literature
حسب: Marianna Peroni, MD, وآخرون
منشور في: (2025-08-01)

HDAC5, an early osimertinib-responsive gene, is a novel therapeutic target for the drug resistance in EGFR-mutant lung adenocarcinoma cells
حسب: Hanbing Lyu, وآخرون
منشور في: (2025-06-01)

Adenovirus pneumonia mimicking osimertinib‐induced pneumonitis in a patient with advanced NSCLC with EGFR mutation: A case report
حسب: Toru Imai, وآخرون
منشور في: (2024-03-01)

Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLC
حسب: M. Jebbink, MD, وآخرون
منشور في: (2023-04-01)

Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors
حسب: Svenja Wagener-Ryczek, وآخرون
منشور في: (2020-05-01)

Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study
حسب: Jingran Ji, MD, وآخرون
منشور في: (2023-03-01)

Chemotherapy versus personalized therapy for EGFR mutant lung adenocarcinoma resistance to EGFR-tyrosine kinase inhibitors: a retrospective dual-center study
حسب: Kan Jiang, وآخرون
منشور في: (2024-02-01)

First-line Osimertinib for Lung Cancer With Uncommon EGFR Exon 19 Mutations and EGFR Compound Mutations
حسب: Tia Cheunkarndee, BA, وآخرون
منشور في: (2024-06-01)

High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience
حسب: A.J. Piper-Vallillo, MD, وآخرون
منشور في: (2022-06-01)